Project Grant R01AG102339
- The National Institute on Aging awarded the Scripps Research Institute $2.613 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to investigate a druggable mito-nuclear feedback mechanism that preserves mitochondrial and synaptic function in aging and Alzheimer's disease. The research focuses on elucidating how age and pathological tau destabilize a brain-specific mito-nuclear feedback loop that controls mitochondrial gene expression in response to acetyl-CoA...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $704,145 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop and apply computational methods for inferring the natural history of Alzheimer's disease from sparse longitudinal molecular and neuroimaging data. The recipient will develop an innovative approach that leverages temporal signal in sparse longitudinal datasets to reconstruct the timeline of Alzheimer's disease progression and...
- The National Institute on Aging awarded The Research Foundation For The State University Of New York (operating as Stony Brook University) $454,937 on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate the regulatory landscape of neurodegeneration using single-cell spatial multiomics approaches. The research integrates chromatin accessibility and protein-level measurements to characterize how cells near Alzheimer's disease hallmarks—amyloid-beta and tau—regulate...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $230,388 on March 4, 2026, under the Aging Research program (CFDA 93.866) to dissect the role of the PICALM/EED locus on myeloid cells in Alzheimer's disease. The recipient will conduct research to understand how an Alzheimer's disease risk enhancer on chromosome 11 influences expression of two target genes—PICALM (phosphatidylinositol binding clathrin assembly protein) and EED (embryonic ectoderm development)—and to...
- The National Institute on Aging, a component of the Department of Health and Human Services National Institutes of Health, awarded $301,575 to the Palo Alto Veterans Institute for Research on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a two-year project grant testing the combined effectiveness of the anti-amyloid medication lecanemab and exercise training for Alzheimer's disease treatment. The recipient will use the 3XTG-AD mouse line to evaluate whether...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $100,228 on February 18, 2027, under the Aging Research program (CFDA 93.866) for epigenetic regulation research on microglial dysfunction in Alzheimer's disease. The award funds laboratory research investigating how the protein ARID5B regulates histone modifications that influence microglial identity and function in Alzheimer's disease pathogenesis. The recipient will use CRISPR/Cas9 and CRISPR...
- The National Institute on Aging awarded The Regents of the University of California, San Francisco $1,419,145 on June 1, 2026, under the Aging Research program (CFDA 93.866) to conduct cell-type-specific drug repurposing for Alzheimer's disease using single-nucleus transcriptomic profiling and computational drug repositioning. The project employs state-of-the-art single-nucleus transcriptomic analysis (VINE-SEQ) and integrative computational tools including Connectivity Map and LINCS to identify...
- The National Institute on Aging awarded New York University $642,063 under the Aging Research program (CFDA 93.866) on January 15, 2026, to investigate gabaergic circuit targets for modulating entorhinal cortex and hippocampal dynamics in Alzheimer's disease. The research examines vasoactive intestinal peptide and cholecystokinin inhibitory neuron microcircuits within hippocampal area CA1, with the hypothesis that modulating activity in these circuits can improve lateral entorhinal cortex–CA1...
- The National Institute on Aging awarded The Broad Institute, Inc. $698,718 on September 3, 2026, under the Aging Research program (CFDA 93.866) to develop an innovative live-cell imaging platform for functional genomics screening of amyloid precursor protein (APP) processing relevant to Alzheimer's disease. The award funds development and validation of SPT-OPS, a multiplexed imaging technology integrating single-particle tracking (SPT) with optical pooled screening (OPS). The platform uses two...
- The National Institute on Aging awarded Purdue University $387,183 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop mass spectrometry-based proteomics strategies examining post-translational modifications related to protein aggregation and extracellular vesicle-mediated propagation in neurodegenerative disease, with emphasis on Alzheimer's disease. The recipient will establish a novel proteomics platform to profile N-terminal acetylation landscapes in primary...
The National Institute on Aging awarded $1,212,742 to the Sloan-Kettering Institute for Cancer Research on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate epichaperomes as a mechanism for restoring drug responsiveness in Alzheimer's disease. The research tests the hypothesis that epichaperome inhibition with PU-AD restores synaptic architecture and re-enables responsiveness to levetiracetam (LEV), a therapy whose efficacy depends on properly localized SV2A protein. Aim 1 defines the mechanism and reversibility of epichaperome-driven synaptic dysfunction through quantitative high-resolution imaging, vesicle-cycling assays, excitability measurements, and biochemical protein-protein interaction analyses across human postmortem Alzheimer's disease brains, transgenic mouse models (APPNL-F/NL-F and 5XFAD), and human induced pluripotent stem cell-derived glutamatergic neurons exposed to soluble oligomeric amyloid-beta. Aim 2 evaluates restoration of drug responsiveness in vivo and establishes an optimized, clinically translatable treatment regimen using both transgenic mouse models treated at symptomatic stages, with outcomes spanning cognition, synaptic plasticity, network excitability, and biomarker analyses including PU-PET imaging for epichaperomes and [18F]SYNVEST-1 for SV2A. The award period runs through May 31, 2031, with performance in New York, New York.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.2m | 8/25/26 |